Major shareholder announcement

Novozymes hereby announces that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes.

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.45%, previously reported at 7.56% (a decrease of 0.11%).
Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 24,196,308 shares of a nominal value of DKK 48,392,616, equivalent to 7.45% of Novozymes A/S’ share capital and 2.99% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, decreasing its holding of B shares in Novozymes A/S to a total of 15,986,454 B shares of a nominal value of DKK 31,972,908, equivalent to 4.92% of Novozymes share capital.

Contact information


Investor Relations:
​Thomas Bomhoff (DK) ​+45 3077 1226 tsbm@novozymes.com
​Klaus Sindahl (DK) ​+45 5363 0134 ksdh@novozymes.com
​Martin Riise (USA) ​+1 919 649 2565 mrsn@novozymes.com
Press and media:
​Rene Tronborg (DK) ​+45 3077 2274 retr@novozymes.com
​Frederik Bjoerndal (Europe) ​+45 3077 0236 tfbh@novozymes.com
​Paige Donnelly (USA) ​+1 919 218 4501 pagd@novozymes.com
​Meng Lian (China) ​+86 136 9923 1164 mexl@novozymes.com
​Henrique Pellini (Brazil) ​+55 41 9288 0282 hqp@novozymes.com
​Poonam Kapila (India) ​+91 991 082 2339 poka@novozymes.com